Get the full picture
Sign in to uncover key details.
Panacea Ventures
Finance · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2255 N Cahuenga Blvd Apt 20, Los Angeles...Website
www.panaceaventure.comRevenue
$12.4 MillionIndustry
About Panacea Ventures
Panacea Capital is a global healthcare venture fund focused on driving innovation in the biotech sector. The firm is dedicated to transforming lives through investments in life sciences, with a portfolio that includes over 30 private and several public companies. Their investment strategy encompasses next-generation immunotherapeutic modalities, innovative regenerative medicine, and treatments for neurodegenerative diseases. With a team of experienced partners, Panacea Capital aims to build and expand companies while addressing unmet medical needs on a global scale.Explore more
Panacea Ventures Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Panacea Ventures
Compare insights from companies similar to Panacea Ventures, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Panacea Ventures Tech Stack
A closer look at the technologies used by Panacea Ventures
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Panacea Ventures
Sign Up For FreeTo access detailed company insights
Panacea Capital is a global healthcare venture fund focused on driving innovation in the biotech sector. The firm is dedicated to transforming lives through investments in life sciences, with a portfolio that includes over 30 private and several public companies. Their investment strategy encompasses next-generation immunotherapeutic modalities, in... Read More
